Keyword: Axovant Sciences
David Hung, M.D. is getting back into cancer with his new oncology startup.
Axovant raised the biggest biotech IPO of 2015 but crashed and burned a few years later. Time will tell if a 2018 pivot to gene therapy will be the company's saving grace.
Axovant has clinical readouts from its switch into gene therapy after failed endeavors in Alzheimer’s—and the initial data look encouraging.
Rachelle Jacques, who most recently was a senior vice president at Alexion, takes over from Alvin Shih, M.D., who signed on at Enzyvant in November 2016.
Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.
Axovant spun off its small molecule team into Arvelle Therapeutics, as it continues its march toward a sole focus on gene therapies.
Axovant Sciences has renamed itself Axovant Gene Therapies to put a seal on its bid to become a player at the cutting edge of genetic medicine.
Since Pavan Cheruvu took Axovant’s helm in February 2018, the company has been plugging away at becoming a gene therapy player.
The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic.
Axovant has halted development of nelotanserin after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia.